Skip to content

Julie Brahmer, MD

THORACIC ONCOLOGY

  • Home
  • Dr. Brahmer & Johns Hopkins
  • Professional Associations
  • Articles & Affiliations
  • Articles & Affiliations Continued…
  • Videos
  • Reviews
  • Contact

Articles & Affiliations Continued…

Articles by Dr. Julie Brahmer, MD

  • Brahmer Provides a Glimpse of Future Immunotherapeutics in NSCLC
  • Brahmer Highlights Next Steps for Osimertinib in EGFR-Mutant NSCLC
  • Brahmer Highlights Practice-Changing Data in HER2-Mutated NSCLC
  • Brahmer Shares Next Steps for Immunotherapy in Metastatic NSCLC
  • Five-Year Survival Rate an Impressive 16% With Nivolumab in Advanced NSCLC

 

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

OncLive – Author | Julie R. Brahmer, MD – Videos & Articles

Targeted Oncology – Articles by Julie R. Brahmer, MD

 

 

 

  • Brahmer Highlights Immunotherapies in the Pipeline for NSCLC
  • Durvalumab Shows Promise in Patients With NSCLC, Brahmer Says
  • Nivolumab/Ipilimumab Combination Shows Benefit in First-Line Setting for NSCLC
  • Clarifying Mechanisms of Resistance May Enhance Treatment Strategies

Women Physicians in Oncology and Hematology Remain Underrepresented in Leadership Roles

Dr. Julie Brahmer named Meyerhoff Professor in Thoracic Oncology

https://youtu.be/SHIXoVH_9GY

Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape

Follow Me:

  • linkedin
  • Home
  • Dr. Brahmer & Johns Hopkins
  • Professional Associations
  • Articles & Affiliations
  • Articles & Affiliations Continued…
  • Videos
  • Reviews
  • Contact
Julie Brahmer, MD Proudly powered by WordPress